Stock Analysts

AXIS Capital Posts Strong Q4 Earnings

AXIS Capital Holdings Limited ( AXS ) reported fourth-quarter 2013 net operating income of $1.41 per share, which fell short of the Zacks Consensus Estimate by 5.4%. However, results were better from an operating loss of 23 cents per share reported in the prior-year quarter. Including net realized investment gains, AXIS Capital reported net income of $1.52 a share, which also grew significantly from a net loss of 16 cents a share recorded in the year-ago quarter. […]

Stock Analysts

Cerner Beats on Q4 Earnings and Revs

Cerner Corporation ( CERN ) reported adjusted net earnings of $128.1 million or 36 cents per share for the fourth quarter of 2013, topping the Zacks Consensus Estimate of 34 cents per share. This reflected a 14.6% rise from $111.8 million and 12.5% from 32 cents in the comparable quarter a year ago. […]

Stock Analysts

AECOM Beats on Q1 Earnings, Guides Up

AECOM Technology Corporation ( ACM ) reported earnings of 37 cents per share for first-quarter fiscal 2014 (ended Dec 31, 2013), beating the Zacks Consensus Estimate of 36 cents by a penny. The company reported net income of $56 million which was a significant improvement from last year’s figure of $38 million. Growth in the company’s core business as well as its joint ventures drove the earnings up. […]

Stock Analysts

UDR Inc. Misses on Q4 FFO

UDR Inc. ’s ( UDR ) fourth-quarter 2013 funds from operations (FFO) as adjusted came in at 35 cents per share, missing the Zacks Consensus Estimate by a penny. However, this was in line with year-ago quarter figure […]

Stock Analysts

HCA Holdings Beats on Q4 Earnings

HCA Holdings Inc. ( HCA ) reported fourth-quarter 2013 operating net income of 92 cents per share which surpassed the Zacks Consensus Estimate of 86 cents by nearly 7%. The results also exceeded the prior-year earnings by a penny. […]

Stock Analysts

Crown Holdings Drops to 52-Week Low

Shares of Crown Holdings, Inc. ( CCK ) hit a new 52-week low of $37.29 on Feb 4, following its sluggish fourth-quarter 2013 results. Philadelphia-based Crown, a leading supplier of packaging products with a market cap of roughly $5.66 billion, has seen its share price fall roughly 7.85% year to date. […]

Stock Analysts

AGL Resources Lags on Q4 Earnings, Ups Div

Energy services holding company, AGL Resources Inc ( GAS ), reported weak fourth-quarter 2013 earnings, owing to significant increase in operating cost. The company announced earnings per share of 68 cents, failed to meet the Zacks Consensus Estimate of 91 cents. Moreover, the figure also decreased 25.3% from the year-ago adjusted profit. […]

Stock Analysts

Equity Residential Q4 FFO a Penny Ahead

Equity Residential ’s ( EQR ) normalized funds from operations (FFO) per share in fourth-quarter 2013 reached 77 cents, a penny ahead of the Zacks Consensus Estimate and 2 cents above the prior-year quarter figure. Quarterly results at this apartment real estate investment trust (REIT) were primarily driven by higher same store net operating income (NOI) and benefit from the Archstone properties. […]

Stock Analysts

Myriad Tops on Earnings & Revs, Ups View

Myriad Genetics ( MYGN ) reported earnings per share (EPS) of 66 cents in the second quarter of fiscal 2014, registering a remarkable 40.4% beat over the Zacks Consensus Estimate and a stupendous year-over-year growth of 57.1%. Net income came in at $50.4 million, surging 43.8% from the comparable year-ago period.Apart from healthy sales growth, EPS growth was boosted by a reduced share count. […]

Stock Analysts

Xylem Beats Q4 Earnings & Revenues

Water solutions provider, Xylem Inc. ( XYL ) reported fourth-quarter 2013 results, showing year-over-year improvement in both earnings and revenues. The company posted adjusted earnings of $103 million or 56 cents a share compared with $88 million or 47 cents in the year-ago quarter. […]

Stock Analysts

Lower Storm Rev Erodes Pike’s Q2 Earnings

Energy solutions provider Pike Electric Corporation ( PIKE ) once again posted disappointing results for the fiscal second quarter 2014 (ended Dec 31, 2013). The company’s earnings per share in the quarter were 18 cents, down considerably from 67 cents earned in the year-ago quarter. The bottom line, however, surpassed the Zacks Consensus Estimate of 8 cents […]

Stock Analysts

Coca-Cola Enterprises Beats on Q4 Earnings

Coca-Cola Enterprises ’ ( CCE ) fourth-quarter 2013 adjusted earnings of 54 cents per share beat the Zacks Consensus Estimate of 52 cents by 3.8% and the year-ago earnings of 45 cents by 20.0% driven by solid revenue increase. Quarter Details During the quarter, net sales grew approximately 6.0% year over year to $2.03 billion but fell marginally short of the Zacks Consensus Estimate of $2.05 billion by 1.0%. Excluding currency translations, revenues grew 3.5% driven by improvement in volumes […]

Stock Analysts

Vocus’ Q4 Loss Narrower Than Expected

Vocus Inc. ( VOCS ) reported fourth-quarter 2013 adjusted loss per share (excluding amortization, fair value adjustments but including stock-based compensation) of 4 cents, narrower than the Zacks Consensus Estimate of 9 cents loss per share. The quarterly loss was below management’s guidance of earnings of 3 to 4 cents and earnings of 1 cent per share reported in the year-ago quarter […]

Downgrades

COHERENT INC (COHR) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of COHERENT INC (COHR) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $79.30. COHERENT INC. designs, manufactures, and supplies electro-optical systems and medical instruments utilizing laser, precision optic and microelectronic technologies […]

Downgrades

CARDIOVASCLR SY (CSII) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of CARDIOVASCLR SY (CSII) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $36.80. Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease […]

Downgrades

WESTERN GAS EP (WGP) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of WESTERN GAS EP (WGP) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $44.30. Western Gas Equity Partners, LP is formed to own, operate, acquire and develop midstream energy assets. Western Gas Equity Partners, LP is based in The Woodlands, Texas. […]

Downgrades

NEKTAR THERAP (NKTR) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of NEKTAR THERAP (NKTR) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $14.90. Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain […]